Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib in Advanced Systemic Mastocytosis
NCT03580655Phase 2Completed
- Sponsor
- Blueprint Medicines
- Start
- Nov 2018
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 12
01
Overview
A Phase 2 trial of avapritinib in systemic mastocytosis (SM), mast cell leukemia (MCL), sponsored by Blueprint Medicines. Started Nov 2018; status: completed.
02
Drugs
avapritinib
03
Conditions
systemic mastocytosis (SM)mast cell leukemia (MCL)
Beyond the preview
Go deeper on NCT03580655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03580655.